QPS Launches New Leukopak and Cell Therapy Products Facility
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/
The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)
To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.
QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.
“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”
Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.
QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113328476/en/
Contacts
Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qps.com&esh
eet=54151703&newsitemid=20241113328476&lan=en-US&anchor=www.qps.com&index=2&md5=
8586b94df60fd6abd834882cd1e26b64
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Heidrick & Struggles Appoints a New Managing Partner for Their CEO & Board Practice in Europe and Africa2.5.2025 11:27:00 EEST | Press release
Heidrick & Struggles (Nasdaq: HSII), a premier provider of executive search, global leadership advisory and on-demand talent solutions, has appointed Kati Najipoor-Smith as Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa. Based at the Firm’s office in Frankfurt, Germany, Kati brings decades of global executive search and consulting experience to the Heidrick & Struggles team to support boards and CEOs in navigating complex leadership challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501269229/en/ Kati Najipoor-Smith has been appointed Heidrick & Struggles' Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa Kati began her executive search career at Egon Zehnder in 1999, where she led Global Automotive and later the Global CEO Practice over several years. She advises chairs and CEOs of publicly traded, family-owned, and private-equity-backed companies across sectors
Valeo Foods Group Acquires Freddi Dolciaria S.p.A, Enhancing its Position in the Italian Bakery Sector2.5.2025 11:00:00 EEST | Press release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the Italian sweet bakery producer Freddi Dolciaria S.p.A (“Freddi”), accelerating growth in South-West European region and enhancing its position in the bakery sector. Freddi is an Italian sweet bakery company founded in 1949 by Luigi Freddi and headquartered in Castiglione delle Stiviere, Italy. Specialising in sponge cakes, Freddi has an established presence in both the Italian retail and international markets, with an annual turnover approaching €20 million and 48 employees. This acquisition strengthens Valeo Foods Group’s position in the packaged wafers, cakes, and biscuits category, complementing the existing Balconi business across Southern Europe and international markets. The integration of Freddi is expected to drive sustainable, profitable growth while enhancing production capacity and operational efficiency. It also reinforces Valeo’s continued expansion in th
Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 23:24:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest was $1.5 million and $9.0 million in the fourth quarter and for the full year 2024. Although 2024 net income was a decrease of $1.5 million, compared to $10.5 million last year, the reduction was due to a one-time non-cash tax benefit of $5.9 million in the prior year after be
IFF Declares Dividend for Second Quarter 20251.5.2025 23:15:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/
Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 23:01:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same period last year. International revenue was $54.1 million for the 2025 first quarter, an increase of 2.2% compared to $52.9 million for the same period last year. Subscription revenue was $99.0 million, which accounted for 95.0% of total revenue for the 2025 first quarter, compared to subscription rev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom